PATENT CLAIM ANALYSIS

Application Number: 15745451
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["424", "133100"]

Abstract:
The present invention relates to a combination of an anti-human VEGFR2 antibody, preferably ramucirumab, and N-(3-fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2- dihydropyridine-3-carboxamide, and to methods of using the combination to treat certain disorders, such as gastric cancer.

Claim (Index 6):
The method of  claim 4 , wherein ramucirumab is administered once every three weeks at a dose of about 6 mg/kg to about 12 mg/kg.

Metadata:
- Claim Count in Document: 31.0
- Percentile: 86.0
- Lexical Diversity: 1.35897
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13098247', '14214127', '14411515', '13891366', '13891349']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7635327942836044
- 35 USC 102 Novelty (BERT): 0.5203853596555298
- Combined Prediction Score: 0.739218050820797
- Mean Citation Score: 286.59723
- Max Citation Score: 299.8195
- Similarity Product: 187.2361806359888

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test